Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

MMM > HTLV > Flashcards

HTLV Flashcards

1
Q

What are the main diseases associated with HTLV-1?

A

Adult T-cell leukemia/Lymphoma (ATL) and HTLV-1 associated myelopathy (HAM/TSP)

ATL occurs in ~5% of all infected individuals, while HAM/TSP affects 0.25-3.8% of infected individuals.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the primary mechanism of disease development in HTLV-1?

A

Interaction between viral and host proteins leading to T-cell proliferation and transformation

This oncogenic process is particularly relevant in the case of Adult T-cell leukemia/Lymphoma (ATL).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the estimated global prevalence of HTLV-1 infection?

A

At least 5-10 million people

Prevalence data is not available for many countries, leading to potential underestimation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

In which regions is HTLV-1 endemic?

A
  • Caribbean
  • South America
  • Much of Africa
  • Indigenous population of Australia
  • Melanesia (Fiji, PNG, Solomon Islands)
  • Romania
  • Iran
  • Japan
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the estimated prevalence of HTLV-1 infection among UK blood donors?

A

5 per 100,000 first and repeat donors

This rate has remained stable over the last 30 years.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the prevalence of HTLV-1 in the Antenatal setting?

A

50 per 100,000

This indicates a higher prevalence compared to the general UK population.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the prevalence of HTLV-1 in sexual health settings?

A

As high as 800 per 100,000

Limited evidence suggests this elevated prevalence in sexual health contexts.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the structure of the HTLV-1 virion?

A

Enveloped spherical virion (100nm) with a ssRNA genome

HTLV-1 belongs to the Retroviridae family and the Delta-retrovirinae genus.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How many subtypes of HTLV-1 are there?

A

Seven subtypes

Each subtype has a unique geographic distribution influenced by population migration.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which HTLV-1 subtype is the most globally widespread?

A

Cosmopolitan subtype A

Subtype A has several subgroups, including transcontinental, Japanese, West and North African, Senegalese, and Afro-Peruvian.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the predominant subtype of HTLV-1 in Australia and Oceania?

A

Subtype C

This subtype is localized to distinct regions in Australia and Oceania.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What type of cell does HTLV-1 primarily infect?

A

CD4-T cells and ?CD8 cella

Infection occurs primarily through direct cell-to-cell contact.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How are new HTLV-1 infections typically acquired?

A

Transfer of infected lymphocytes

Viral RNA is NOT found in the plasma; thus, cell-free particles are not the usual source of new infections.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What receptor does HTLV-1 use to enter target cells?

A

GLUT1
Neuropilin-1
Heparan sulphate protoglycans

GLUT1 is a glucose transporter on target cells that mediates entry of the virus.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What happens to HTLV-1 RNA after it enters a cell?

A

It is reverse transcribed into DNA and integrates into the host genome as a provirus

This integration leads to lifelong infection with a long latent period before disease manifestation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the main routes of HTLV-1 transmission?

A

M to C (mainly BF, in-utero, giving birth),
Sex,
IVDU,
Blood transfusion and Organ transplantation, Occupational exposure,
Certain cultural and religious practices (flagellation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the risk associated with exclusive breastfeeding for infants with HTLV-1?

A

Very minimal risk for the first 3 months; thereafter, some risk

Mothers should have monitored blood and breast milk proviral load.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the chance of developing adult T-cell leukemia (ATL) from early life HTLV-1 infection?

A

1 in 5 chance

This is one of the arguments for antenatal screening.
Early life infection is key to the development of adult T-cell leukaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What clinical conditions are associated with HTLV-1?

A

ATL,
HAM/TSP,
Uveitis,
Bronchectasis,
Infective dermatitis,
Arthritis,
Peripheral neuropathy,
Disseminated Strongyloidiasis
Unexplained 57% increase in the adjusted MR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are the clinical features of ATL?

A

Generalised lymphadenopathy,
Hepato-splenomegaly,
Bone and skin lesions,
Immunosuppression,
Hypercalcemia

The acute and lymphoma forms of ATL are the most aggressive.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the prognosis for patients with HAM/TSP?

A

Prognosis variable, extremely poor quality of life

Substantial proportion of patients may not be able to walk unaided 10 years after onset–> 50% wheelchair

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

True or False: The risk of sexual transmission of HTLV-1 is greater from females to males.

A

False

Risk is greater from males to females.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is the treatment for Strongyloidiasis linked to HTLV-1 infection?

A

Ivermectin (2 days treatment repeated after 2 weeks)

No need to repeat serology for one year.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
What immunological effect does HTLV-1 have on T-helper cells?
Activates Th1 cells, leading to overproduction of Th1-related cytokines (mainly IFN-γ and TNF-α) ## Footnote This results in suppression of Th2 lymphocytes and reduced Th2 cytokine production (mainly IL-4, IL-5, IL-10 and IL-13) ---> reduction in the ability of the infected host to mount an adequate immune response to invading organisms that require a predominantly Th2-dependent response (these include parasitic infections and the production of mucosal and humoral antibodies)
26
Fill in the blank: HTLV-1 has an _______ effect which becomes _______.
immunostimulating, immunosuppressive ## Footnote This is a key difference from HIV.
27
What is the relationship between proviral load and mortality rate in HTLV-1 infected individuals?
Stronger suspicion of a relationship but not fully understood ## Footnote Particularly in relation to the 57% increase in all-cause adjusted mortality rate.
28
What are some common symptoms of HAM/TSP?
Progressive weakness and spasticity of both legs Incontinence impotence ## Footnote Substantial proportion will not be able to walk unaided within 10 years.
29
30
What test confirms a reactive HTLV Ab in blood?
Western Blot or Line assay ## Footnote These tests also type the infection.
31
What is performed if serology for HTLV is inconclusive?
PCR for proviral DNA ## Footnote Whole blood is required to allow extraction of DNA from lymphocytes.
32
Is treatment indicated for all patients with HTLV?
Not indicated if no clinical condition ## Footnote However, all patients are recommended to attend specialist services.
33
Why it is recommendations for ALL patients with HTLV to regularly attend clinic ?
* Promptly identify onset of symptoms * Access to clinical trials if treatment is required * Seek advice on preventing transmission ## Footnote Preventive measures include no breastfeeding, using condoms, and not donating blood.
34
What screening is offered to newly diagnosed HTLV patients?
Screening for associated diseases, such as strongyloidiasis
35
What types of ARV have activity against HTLV-1?
* NRTI * Integrase inhibitors (INSIT) ## Footnote They have been tested in clinical trials BUT do not reduce proviral DNA levels.
36
Which ARV classes have no anti-HTLV activity?
* NNRTI * Protease inhibitors (PI)
37
What is the treatment for ATL?
* Chemotherapy * Monoclonal antibodies (mAb) * Bone marrow transplant (BMT) ## Footnote Treatment outcomes are often poor.
38
What is the median life expectancy following presentation of ATL?
8-10 months
39
What is the first-line treatment for AT leukemia?
* AZT * Interferon-alpha
40
What is important for prophylaxis in HTLV patients?
Prophylaxis against opportunistic infections
41
What is Mogamulizumab?
A humanized anti-CCR4 antibody ## Footnote It targets CD4+ and CD8+ T cells infected with HTLV-1 and enhances anti-tumor immunity.
42
What conditions is Mogamulizumab used to treat?
* Relapsed/refractory CCR4-positive aggressive ATL * May be effective against HAM-TSP
43
What treatments may slow progression of HAM?
* Corticosteroids * Steroid-sparing anti-inflammatory agents ## Footnote Mogamulizumab (MOG) phase 1-2a study in Japan evaluated MOG for the treatment of HAM/TSP and reported decreases in HTLV-1 proviral load and neuroinflammatory markers, with clinical improvement in some participants
44
What have international recommendations recently focused on?
Management of ATL and HAM
45
What is the status of treatment availability for conditions caused by HTLV?
Better treatments are urgently needed ## Footnote General recommendations beyond the management of HAM and ATL cannot yet be made.
46
What is considered a significant occupational exposure to HTLV-1?
Exposure to cellular fluid (whole blood) of an HTLV-infected patient through NSI particularly when the pVL DNA is high
47
What is recommended for individuals with significant occupational exposure to HTLV-1?
PEP with RTG + AZT + 3TC for 6 weeks
48
In which populations is HTLV-2 mainly found?
Indigenous Americans and Western Africa
49
How does the prevalence of HTLV-2 compare to HTLV-1 in the UK?
Less common than HTLV-1
50
What is the association of HTLV-2 with disease?
Less frequently associated with disease; if occurs, it's milder
51
What is known about HTLV-2 in disease?
Little information available
52
53
What organization coordinates national HTLV surveillance activities?
PHE
54
From where are LAB reports of NEW HTLV diagnoses received?
VRD: the Virus Reference Department/Colindale --. where confirm ALL HTLV diagnosis in England & Wales.
55
How often is clinical data on new HTLV diagnoses received?
Annually
56
Which centers provide specialist care for HTLV diagnoses?
Imperial College, Birmingham, York, Manchester ## Footnote These centers are key providers of specialist care related to HTLV.
57
What additional data is collected related to HTLV diagnoses?
HTLV diagnosis data for NHSBT ## Footnote NHSBT stands for National Health Service Blood and Transplant.
58
59
What did the WHO launch on 17 March 2021 regarding HTLV-1?
A technical report recognizing the unknown risk of nosocomial infection and the association of pro-viral load with transmission ## Footnote The report emphasizes that further research on these issues is prioritized.
60
What should be considered for HTLV-1 control and prevention?
Infection control in health care settings and harm reduction for PWID
61
What is the current prevalence of HTLV-1 among UK healthcare workers?
Currently unknown but likely to be low ## Footnote The burden of infection and risk of onward transmission to patients is also considered unlikely to be higher than in the general UK population.
62
Is there evidence of HTLV-1 transmission from healthcare workers to patients during an EPP?
No evidence in the literature ## Footnote The risk in this context remains unknown and is limited to a small number of circumstantial case reports.
63
What is the assumption regarding the risk of transmission and seroconversion with low VL in donor HCWs?
The risk will be lower ## Footnote This is based on expert opinion and knowledge from transmission dynamics of other viruses.
64
How early does the VL stabilize after HTLV-1 acquisition?
Certainly within 6 months ## Footnote One cohort study showed that pVL remained stable over an 8-year period.
65
What are 'Elite controllers' in the context of HTLV-1?
Individuals with an undetectable pVL ## Footnote The natural history of infection and transmission risk in this cohort has not been studied.
66
What is considered a high pVL cut-off for HTLV-1?
> 4% (4 HTLV-1 DNA copies per 100 peripheral blood mononuclear cells) ## Footnote This level is associated with an increased risk of disease, especially ATL.
67
Are patients with HAM/ATL more likely to have higher pVL than those without?
Yes ## Footnote The median pVL in asymptomatic carriers is 1.5%, but some may have pVL similar to those with HTLV-1 associated diseases.
68
Is there a curative treatment for HTLV-1 infection?
No curative treatment available ## Footnote Transmission events will result in lifelong infection, and patients are monitored for sequelae such as ATL and HAM.
69
What is the impact of HTLV-1 transmission from HCW to patient?
Likely significant with associated risk of lifelong infection, increased morbidity and mortality ## Footnote There are no curative treatments available.
70
Is there research available on the effectiveness of existing standard IPC in preventing HTLV-1 transmission in healthcare settings?
No research available ## Footnote Applying knowledge from other BBV suggests that standard PPE and safe disposal of sharps will minimize transmission likelihood.
71
What risk do EPPs carry in terms of HTLV-1 transmission?
Additional risk of injury and exposure of the patient’s open tissues to the blood of the HCW, in addition to what is mitigated by standard precautions.  ***EPPs therefore present a theoretically higher chance of exposure but this is NOT studied.
72
73
What is the recommendation regarding health clearance for HTLV-1 for EPP-performing HCWs?
Health clearance for HTLV-1 should NOT be introduced at this time
74
What are the reasons for not introducing health clearance for HTLV-1 in HCWs?
* Lack of evidence of prevalence among EPP-performing HCWs * Unknown risk of transmission to patients * Lack of treatment/monitoring criteria for HCWs post-diagnosis * Deemed not proportionate/appropriate OH intervention
75
What does UKAP note about high VL carriers and ATL/HAM?
The majority of high VL carriers DO NOT have either condition or do not develop such conditions until years later
76
What percentage of HTLV infections are undiagnosed in England?
90% ## Footnote SO ,, it is unreasonable to assume that a HCW would be tested for HTLV as a consequence of such a diagnosis.
77
Does UKAP currently advise any restrictions from EPP practice for HCWs with known HTLV-1 infection?
No, UKAP does NOT currently advise any restrictions ## Footnote HCWs should disclose their HTLV-1 status for risk assessment OH and ethical duties).
78
What should OH consider recording for HCWs with HTLV-1? and why?
The HCWs pVL To inform any future risk assessments.
79
What is the rationale for not restricting EPP practice for HCWs with HTLV-1?
* Lack of evidence that restrictions improve patient safety * Unknown risk of transmission via EPP * Insufficient evidence of high VL prevalence among HCWs * No cut-off level for safe practice can be established
80
Does UKAP recommend routine occupational health monitoring of HCWs infected with HTLV-1?
No, UKAP does not currently recommend routine monitoring ## Footnote Due to lack of evidence regarding transmission risk and high VL likelihood.
81
What should be done in case of patient exposure to HCWs infected with HTLV-1?
Seek advice from a local virologist, local HPT, and national experts on HTLV on a case-by-case basis ## Footnote A risk assessment may also be considered.
82
Why is it important to contact virology or national experts urgently after patient exposure?
To determine whether the exposed patient requires PEP (Post-Exposure Prophylaxis) ## Footnote The administration of PEP is time-limited.
83
84
What is the primary purpose of the HTLV DNA qPCR test?
HTLV-I DNA viral load measurement for diagnosis and monitoring of disease in patients infected with HTLV-1 and HTLV-2.
85
What method is used to measure HTLV-1/2 viral load?
An in-house method using real-time quantitative PCR monitored by SYBR Green I dye incorporation.
86
Which genes are targeted by primers in the HTLV DNA qPCR test?
HTLV-1 and HTLV-2 Tax gene.
87
How is HTLV-1/2 copy number expressed in the test results?
As HTLV-1/2 DNA copies per 100 PBMCs.
88
What is the next step if extracted DNA has an appropriate β-globin gene copy number but NO quantifiable HTLV-1/2 DNA?
A PCR is carried out using nested primers specific for HTLV-1 or HTLV-2.
89
What is the purpose of the HTLV typing by PCR test?
To discriminate between HTLV-1 and HTLV-2 infection.
90
What is the procedure for HTLV typing by PCR?
PCR amplification of the tax gene sequence of HTLV DNA extracted from PBMCs using generic outer primers in the first round and discriminatory inner primers in the second round.
91
How are PCR products detected in HTLV typing?
PCR products are detected on an agarose gel.
92
What controls are run in parallel during HTLV typing?
HTLV-1, HTLV-2, and negative controls.
93
What is the turnaround time for issuing reports for proviral load?
Within two weeks of receiving a sample.
94
What is the turnaround time for genotyping reports?
Within four weeks of receiving a sample.
95
What types of samples are suitable for the HTLV tests?
Whole EDTA blood, CSF, and Fresh tissue/shavings from paraffin-embedded blocks.
96
What should not be sent as a sample for HTLV testing?
Plasma.

MMM (5 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions